ClinConnect ClinConnect Logo
Search / Trial NCT06749132

Deep Learning-enhanced Personalized Monitoring of Aortic Stenosis - The DETECT-AS Prognostic Study

Launched by YALE UNIVERSITY · Dec 19, 2024

Trial Information

Current as of July 21, 2025

Not yet recruiting

Keywords

Aortic Stenosis Artificial Intelligence

ClinConnect Summary

The DETECT-AS Prognostic Study is a clinical trial designed to improve how we monitor and assess the risk for older adults with aortic stenosis, a condition where the heart's aortic valve narrows, making it harder for blood to flow. This study will test a new digital scoring system that helps doctors better understand a patient's risk based on their individual health data. The goal is to personalize care for patients with mild aortic stenosis or aortic sclerosis, which is a less severe form of the condition.

To participate in this study, individuals must be 65 years or older and have had an echocardiogram (a heart ultrasound) within the last 2-3 years showing either aortic sclerosis or mild aortic stenosis. Unfortunately, people with certain conditions, such as a history of heart valve replacement, implantable heart devices, or severe dementia, will not be eligible. Participants will be asked to attend a study visit at an echocardiogram lab within four years of their last echocardiogram, where they will help researchers gather important information about their heart health. This study is currently not recruiting participants but aims to enhance care for older adults with heart conditions in the future.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Age 65 years or older
  • 2. Prior transthoracic echocardiogram within the past 2-3 years showing aortic sclerosis without stenosis or mild AS
  • Exclusion Criteria:
  • 1. Opted out of research studies
  • 2. Non-English speaking
  • 3. Any echocardiogram within 24 months of medical record review.
  • 4. Prior history of aortic valve replacement or repair, including transcatheter and surgical AVR with either a bioprosthetic or mechanical valve
  • 5. Presence of implantable cardiac devices, including permanent cardiac pacer, implantable cardioverter-defibrillator, or left ventricular assist device
  • 6. Prior heart transplant
  • 7. History of dementia
  • 8. Unable to attend study visit at echocardiogram lab within four years of most recent echocardiogram.
  • 9. Documented life expectancy of \<1 year or current participation in hospice services

About Yale University

Yale University, a prestigious Ivy League institution located in New Haven, Connecticut, is renowned for its commitment to advancing medical research and clinical innovation. With a rich history of academic excellence and a robust infrastructure for scientific inquiry, Yale serves as a leading sponsor for clinical trials aimed at improving patient care and developing new therapeutic approaches. The university's multidisciplinary teams of researchers and clinicians collaborate to conduct rigorous and ethical studies, leveraging cutting-edge technologies and methodologies to address critical health challenges. Through its dedication to fostering an environment of inquiry and discovery, Yale University plays a pivotal role in translating research findings into clinical practice, ultimately enhancing health outcomes for diverse populations.

Locations

New York, New York, United States

Houston, Texas, United States

Santa Clara, California, United States

New Haven, Connecticut, United States

Patients applied

0 patients applied

Trial Officials

Rohan Khera, MD, MS

Principal Investigator

Yale University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported